How individual participant data meta-analyses have influenced trial design, conduct, and analysis

Journal of Clinical Epidemiology

Volumn 68, Issue 11, 2015, Pages 1325-1335

  Tierney, Jayne F ^a   Pignon, Jean Pierre ^b   Gueffyier, Francois ^c,d   Clarke, Mike ^e   Askie, Lisa ^f   Vale, Claire L ^a   Burdett, Sarah ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ LYON 1   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Individual participant data (IPD); Meta analysis; Systematic review; Trial analysis; Trial conduct; Trial design

Indexed keywords

ARTICLE; CALCULATION; CONSENSUS DEVELOPMENT; HUMAN; INDIVIDUAL PARTICIPANT DATA META ANALYSIS; META ANALYSIS (TOPIC); METHODOLOGY; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; STUDY DESIGN; SYSTEMATIC REVIEW (TOPIC); CLINICAL TRIAL (TOPIC); PROCEDURES; RESEARCH SUBJECT; STATISTICS;

CLINICAL TRIALS AS TOPIC; HUMANS; META-ANALYSIS AS TOPIC; RESEARCH DESIGN; RESEARCH SUBJECTS; STATISTICS AS TOPIC;

EID: 84938714438     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2015.05.024     Document Type: Article

References (67)

1. M. Clarke Doing new research? Don't forget the old PLoS Med 1 2004 e35
2. N.J. Cooper, D.R. Jones, and A.J. Sutton The use of systematic reviews when designing studies Clin Trials 2 2005 260 264
3. M. Clarke, S. Hopewell, and I. Chalmers Clinical trials should begin and end with systematic reviews of relevant evidence: 12 years and waiting Lancet 376 2010 20 21
4. A.P. Jones, E. Conroy, P.R. Williamson, M. Clarke, and C. Gamble The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials BMC Med Res Methodol 13 2013 50
5. M. Clarke, S. Hopewell, and I. Chalmers Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report J R Soc Med 100 2007 187 190
6. I. Chalmers, and D.G. Altman How can medical journals help prevent poor medical research? Some opportunities presented by electronic publishing Lancet 353 1999 490 493
7. L.A. Stewart, M.J. Clarke on behalf of the Cochrane Working Party Group on Meta-analysis using Individual Patient Data Practical methodology of meta-analyses (overviews) using updated individual patient data Stat Med 14 1995 2057 2079
8. L.A. Stewart, and J.F. Tierney To IPD or Not to IPD? Advantages and disadvantages of systematic reviews using individual patient data Eval Health Prof 25 2002 76 97
9. L.A. Stewart, J.F. Tierney, M. Clarke on behalf of the Cochrane Individual Patient Data Meta-analysis Methods Group Reviews of individual patient data J.P.T. Higgins, S. Green, Cochrane Handbook for Systematic Reviews of Interventions 2008 Wiley-Blackwell Chichester, UK 547 558
10. Tierney JF, Vale CL, Riley R, Tudur Smith C, Stewart LA, Clarke M, et al. Individual participant data (IPD) meta-analyses of randomised controlled trials: guidance on their use. PLoS medicine. In Press.
11. I. Chalmers The Cochrane Collaboration: preparing, maintaining and disseminating systematic reviews of the effects of health care Ann N Y Acad Sci 703 1993 156 165
12. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials BMJ 303 1991 884 893
13. Ovarian Cancer Meta-analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis J Clin Oncol 9 1991 1668 1674
14. The ICON Collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin and cisplatin) in women with ovarian cancer Lancet 352 1998 1571 1576
15. The International Collaborative Ovarian Neoplasm (ICON) Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial Lancet 360 2002 505 515
16. I.R. Konig, A. Ziegler, E. Bluhmki, W. Hacke, P.M. Bath, R.L. Sacco, and et al. Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials Stroke 39 2008 1821 1826
17. The IST-3 Collaborative Group The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial Lancet 379 2012 2352 2363
18. M.R. Sydes, C. Vale, A. Kneebone, M. Pearse, P. Richaud, J.F. Tierney, and et al. Re: postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy Eur Urol 62 2012 e99
19. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview on the randomised trials Lancet 365 2005 1687 1717
20. C. Davies, H. Pan, J. Godwin, R. Gray, R. Arriagada, V. Raina, and et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 2013 805 816
21. ATLAS. Adjuvant Tamoxifen Longer Against Shorter Available at http://www.ctsu.ox.ac.uk/research/mega-trials/atlas/atlas-website. Accessed July 7, 2015.
22. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899 909
23. P. Fournel, G. Robinet, and P. Thomas Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in clocally advanced non-small cell lung cancer: Groupe Lyon Saint Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 study J Clin Oncol 23 2005 5910 5917
24. J. Belderbos, L. Uitterhoeve, and N. van Zandwijk Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973) Eur J Cancer 43 2007 114 121
25. G.V. Scagliotti, R. Fossati, V. Torri, L. Crinò, G. Giaccone, G. Silvano, and et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIa non-small cell lung cancer J Natl Cancer Inst 95 2003 1453 1461
26. J.Y. Douillard, R. Rosell, M. De Lena, F. Carpagnano, R. Ramlau, J.L. Gonzales-Larriba, and et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial Lancet Oncol 7 2006 719 727
27. The International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer N Engl J Med 350 2004 351 360
28. D. Waller, D.J. Fairlamb, N. Gower, R. Milroy, M.D. Peake, R. Rudd, and et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting Proc Am Soc Clin Oncol 22 2003 632
29. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults: meta-analysis of individual patient data Lancet 350 1997 1647 1654
30. W.G. Kraybill, J. Harris, I.J. Spiro, D.S. Ettinger, T.F. DeLaney, R.H. Blum, and et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514 J Clin Oncol 24 2006 619 625
31. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials J Clin Oncol 26 2008 5802 5812
32. F. Gueyffier, C. Bulpitt, J.P. Boissel, E. Schron, T. Ekbom, R. Fagard, and et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials Lancet 353 1999 793 796
33. C.J. Bulpitt, N.S. Beckett, J. Cooke, D.L. Dumitrascu, B. Gil-Extremera, C. Nachev, and et al. Results of the pilot study for the Hypertension in the Very Elderly Trial J Hypertens 21 2003 2409 2417
34. N.S. Beckett, R. Peters, A.E. Fletcher, J.A. S, L. Liu, D.L. Dumitrascu, and et al. Treatment of hypertension in patients 80 years of age or older N Engl J Med 358 2008 1887 1898
35. F. Gueyffier, J.P. Boissier, F. Boutitie, S. Pocock, J. Coope, J. Cutler, and et al. Effect of antihypertensive treatment in patients having already suffered from stroke Stroke 28 1997 2557 2562
36. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
37. M. Lievre, F. Gueyffier, T. Ekbom, R. Fagard, J. Cutler, E. Schron, and et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients: results from a meta-analysis Diabetes Care 23 2000 B65 B71
38. Advance Collaborative Group ADVANCE - action in diabetes and vascular disease: patient recruitment and characteristics of the study population at baseline Diabet Med 22 2005 882 888
39. ADVANCE Management Committee Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation Diabetologia 44 2001 1118 1120
40. J. Bourhis, J. Overgaard, H. Audry, K.K. Ang, M. Saunders, J. Bernier, and et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: an individual patient data meta-analysis of 15 randomized trials Lancet 368 2006 843 854
41. A. Aupérin, R. Arriagada, J.-P. Pignon, C. Le Péchoux, A. Gregor, R.J. Stephens, and et al. Prophylactic cranial irradiaion for patients with small-cell lung cancer in complete remission N Engl J Med 341 1999 476 484
42. C. Le Pechoux, A. Dunant, S. Senan, A. Wolfson, E. Quoix, C. Faivre-Finn, and et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial Lancet Oncol 10 2009 467 474
43. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials Lancet 355 2000 1757 1770
44. S. Burdett, L. Rydzewska, J.F. Tierney, and D.J. Fisher A closer look at the effects of postoperative radiotherapy by stage and nodal status: updated results of an individual participant data meta-analysis in non-small-cell lung cancer Lung Cancer 80 2013 350 352
45. L.M. Askie, P. Brocklehurst, B.A. Darlow, N. Finer, B. Schmidt, W. Tarnow-Mordi, and et al. NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol BMC Pediatr 11 2011 6
46. IMPACT Investigators. Efficacy of adjuvant flurouracil and folinic acid in colon cancer Lancet 345 1995 939 944
47. L. Friboulet, K.A. Olaussen, J.-P. Pignon, F.A. Shepherd, M.-S. Tsao, S. Graziano, and et al. ERCC1 isoform expression and DNA repair in non-small cell lung cancer N Engl J Med 2013 2013 1101 1110
48. J.C. Soria, F. Barlesi, B. Besse, J. Mazieres, P. Merle, J. Cadranel, and et al. Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup J Clin Oncol 31 2013 Suppl Abstr 7505
49. M. Wislez, F. Barlesi, B. Besse, J. Mazieres, P. Merle, J. Cadranel, and et al. Customized adjuvant phase II trial in patients with non-small cell lung cancer: IFCT-0801 TASTE J Clin Oncol 32 2014 1256 1261
50. P.J. Woll, P. Reichardt, A. Le Cesne, S. Bonvalot, A. Azzarelli, H.J. Hoekstra, and et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial Lancet Oncol 13 2012 1045 1054
51. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 189 201
52. C.N. Sternberg, I. Skoneczna, J.M. Kerst, P. Albers, S.D. Fossa, M. Agerbaek, and et al. Immediate versus deffered chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open label, randomised phase 3 trial Lancet Oncol 16 2015 76 86
53. R.H. Groenwold, A.R. Donders, G.J. van der Heijden, A.W. Hoes, and M.M. Rovers Confounding of subgroup analyses in randomized data Arch Intern Med 169 2009 1532 1534
54. J.A. Berlin, J. Santanna, C.H. Schmid, L.A. Szczech, H.I. Feldman Anti-Lymphocyte Antibody Induction Therapy Study G Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head Stat Med 21 2002 371 387
55. D.J. Fisher, A.J. Copas, J.F. Tierney, and M.K.B. Parmar A critical review of methods for the assessment of patient-level interactions in individual patient data (IPD) meta-analysis of randomised trials, and guidance for practitioners J Clin Epidemiol 64 2011 949 967
56. J.J. Kirkham, K.M. Dwan, D.G. Altman, C. Gamble, S. Dodd, R. Smyth, and et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews BMJ 340 2010 c365
57. J.P. Ioannidis, and J. Lau Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas JAMA 285 2001 437 443
58. M. Buyse, G. Molenberghs, T. Burzykowski, D. Renard, and H. Geys The validation of surrogate endpoints in meta-analyses of randomized experiments Biostatistics 1 2000 49 67
59. S. Michiels, A. Le Maître, M. Buyse, T. Burzykowski, E. Maillard, J. Bogaerts, and et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data Lancet Oncol 10 2009 341 350
60. A. Mauguen, J.P. Pignon, S. Burdett, C. Domerg, D. Fisher, R. Paulus, and et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data Lancet Oncol 14 2013 619 626
61. L.M. Askie, L. Duley, D. Henderson-Smart, L.A. Stewart on behalf of the PARIS Collaborative Group Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data Lancet 369 2007 1791 1798
62. D. Ghersi, J. Berlin, L. Askie on behalf of the Prospective Meta-analysis Methods Group Prospective meta-analysis J.P.T. Higgins, S. Green, Cochrane handbook for systematic reviews of interventions 2008 Wiley-Blackwell Chichester, UK 559 570
63. L.A. Stewart, M. Clarke, M. Rovers, R.D. Riley, M. Simmonds, G. Stewart, and et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement JAMA 313 2015 1657 1665
64. P. Brown, K. Brunnhuber, K. Chalkidou, I. Chalmers, M. Clarke, M. Fenton, and et al. How to formulate research recommendations BMJ 333 2006 804 806
65. C.L. Vale, J.F. Tierney, N. Spera, A. Whelan, A. Nightingale, and B. Hanley Evaluation of patient involvement in a systematic review and meta-analysis of individual patient data in cervical cancer treatment Syst Rev 1 2012 23
66. K.A. Robinson, and S.N. Goodman A systematic evaluation of the citation of prior research in reports of randomized, controlled trials Ann Intern Med 154 2011 50 55
67. F. Godlee, and T. Groves The new BMJ policy on sharing data from drug and device trials BMJ 345 2012 e7888